Polyrizon Regains Compliance with Nasdaq Listing Requirements
Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing...
Pharmaceutical
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing marketSAN DIEGO, Aug. 14,...
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon CancerDENVER, Aug. 14,...
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during...
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of...
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty...
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Ickey & Jovante Woods Ickey Woods with his son Jovante. Company and Former Cincinnati Bengals Running Back Known for the...
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
Implemented cost reductions extend cash runway into first half of 2027BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase...
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney...
Avicanna Reports Q2 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical...
Evaxion announces business update and second quarter 2025 financial results
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment...
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of...
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the...
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE...
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant...
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 202450% Growth in Revenue for International Medical CannabisInternational Medical sales...
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may...
AGFA HealthCare Empowers Future Tech Leaders Through Immersive Hands-on STEM Day for Girls in Orlando With Powerteens
"Girls in Focus: A One-Day STEM Experience" introduces middle and high school girls to real-world careers in healthcare technology ORLANDO,...